The Relationship Between FTO and Female Reproduction System Diseases: Focusing on PCOS, Endometriosis and Cancer and Targeted Therapy Strategy

Xueying Miao

doi:10.54097/hf6ayg71

Authors

Xueying Miao

DOI:

https://doi.org/10.54097/hf6ayg71

Keywords:

FTO, PCOS, Endometriosis, Gynecological cancer, m6A.

Abstract

Fat mass and obesity-related (FTO) proteins are indispensable key enzymes in the dynamic regulation of RNA epigenetic transcriptome modification, which significantly affect the RNA life cycle process. In recent years, the involvement of RNA epigenetic modifications in the underlying mechanisms of female reproductive disorders has been extensively researched. Several m6A regulators, including METTL3, FTO are involved in the processes and development of reproduction. FTO-involved m6A modification has been implicated in endometriosis, polycystic ovary syndrome (PCOS), and frequent gynecological cancers include ovarian and endometrial cancer. The pleiotropic effect of FTO has been revealed to be involved in many female diseases, which exert tumor suppressive effects by affecting the IGF1/PI3K-AKT axis and EMT pathway. In ovarian cancer, FTO expression showed distinct associations with tumor growth, with pleiotropic effects. This paper summarizes the association between the m6A modification process of FTO and recent female reproductive diseases——endometriosis, PCOS and cancer, aiming to explore the clinical application and research direction of female reproduction and pathophysiology, increase the current understanding of the cellular mechanism of female reproductive system diseases, diagnostic biomarkers and explore the treatment plan of reproductive system diseases with FTO target as the core.

Downloads

Download data is not yet available.

References

[1] Andraweera PH, Dekker GA, Jayasekara RW, et al. The obesity-related FTO gene variant associates with the risk of recurrent miscarriage [J]. Nordic Federation of Societies of Obstetrics and Gynecology, 2015, 94 (7): 722-726.

[2] Jeschke J, Collignon E, Al Wardi C, et al. Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors [J]. Nature Cancer, 2021, 2 (6): 611–628.

[3] Wang Han, Liang Zongwen, Gou Yanliang, et al. FTO-dependent N (6)-methyladenosine regulates the progression of endometriosis via the ATG5/PKM2 Axis [J]. Cell Signal, 2022, 98: 110406.

[4] Liu Ailing, Xie Huijun, Xie Hongyan, et al. Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis [J]. BMC Medical Genetics, 2017, 18 (1): 89.

[5] Ji Huihui, Zhang Jian-an, Liu Hejing, et al. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer [J]. Frontiers in Immunology, 2022, 13: 976107.

[6] Li Linshuang, Yang Le, Shen Lin, et al. Fat mass and obesity-associated protein regulates granulosa cell aging by targeting matrix metalloproteinase-2 gene via an N6-methyladenosine-YT521-B homology domain family member 2-dependent pathway in aged mice [J]. Reproductive Sciences, 2024, 31 (11): 3498-3511.

[7] Ruan Peng, Wang Shujun, Yang Chaoyi, et al. m6A mRNA methylation regulates the ERK/NF-κB/AKT signaling pathway through the PAPPA/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer [J]. Cell Biology and Toxicology, 2023, 39 (4): 1611-1626.

[8] Zou Zhilin, Zhou Shuguang, Liang Guosheng, et al. The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators [J]. Molecular Omics, 2021, 17 (3): 438-453.

[9] Huang Erqing, Chen Lijuan. RNA N6 -methyladenosine modifcation in female reproductive biology and pathophysiology [J]. Cell Communication and Signaling, 2023, 21 (1): 53.

[10] Zhang Jun, Liu Xinqiong, Gao Yali. FTO protein regulates the TGF-β signalling pathway through RNA N6-methyladenosine modification to induce unexplained recurrent spontaneous abortion [J]. The FEBS Journal, 2024, 291 (7): 1545-1559.

[11] Yuan Huiqin, Zhu Guoping, Wang Fang, et al. Interaction between common variants of FTO and MC4R is associated with risk of PCOS [J]. Reproductive Biology and Endocrinology, 2015, 13: 55.

[12] Esfandiari F, Favaedi R, Heidari-Khoei H, et al. Insight into epigenetics of human endometriosis organoids: DNA methylation analysis of HOX genes and their cofactors [J]. Fertil Steril, 2021, 115 (1): 125-137.

[13] Zhai Junyu, Shang Li, Li Yui, et al. Data mining analysis of the prognostic impact of N6 -methyladenosine regulators in patients with endometrial adenocarcinoma [J]. Journal of Cancer, 2021, 12 (15): 4729-4738.

[14] Zhou Xinying, Zhang Hu, Duan Yingchun, et al. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma [J]. Journal of Clinical Laboratory Analysis, 2023, 37 (1): e24813.

[15] Sá SI, Maia J, Bhowmick N, et al. Uterine histopathological changes induced by acute administration of tamoxifen and its modulation by sex steroid hormones [J]. Toxicology and Applide Pharmacology, 2019, 363: 88-97.

[16] Ma Jian, Yang Di, Ma Xiaoxin. Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial [J]. Aging (Albany NY), 2021, 13 (12): 16287-16315.

[17] Zhang Lin, Wan Yicong, Zhang Zihan, et al. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway [J]. RNA Biology, 2021, 18 (9): 1265-1278.

[18] Wu Jun, Wang Xiaoqin, Li Xin. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer [J]. Epigenomics, 2023, 14 (23): 1509-1522.

[19] Huang H, Wang Y, Kandpal M, et al. FTO-dependent N6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling [J]. Cancer Research, 2020, 80 (16): 3200-3214.

[20] Sun Meige, Zhang Xiaocui, Bi Fangfang, et al. FTO inhibits epithelial ovarian cancer progression by destabilising SNAI1 mRNA through IGF2BP2 [J]. Cancers (Basel), 2022, 14 (21): 5218.

[21] Yang Q, Al-Hendy A. The functional role and regulatory mechanism of FTO m6A RNA demethylase in human uterine leiomyosarcoma [J]. Molecular Sciences, 2023, 24 (9): 7957.

[22] Huang Yue, Yan Jingli, Li Qi, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5 [J]. Nucleic Acids Research, 2015, 43 (1): 373-384.

[23] Huang Yue, Xia Wenyang, Dong Ze, et al. Chemical inhibitors targeting the oncogenic m6A modifying Proteins [J]. Accounts of Chemical Research, 2023, 56 (21): 3010-3022.

[24] Shishodia S, Demetriades M, Zhang D, et al. Structure-based design of selective fat mass and obesity associated protein (FTO) inhibitors [J]. Journal of Medicinal Chemistry, 2021, 64 (22): 16609-16625.

[25] Liu Hong, Zheng Jie, Liao Aihua. The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface [J]. Frontiers in Immunology, 2022, 13: 988130.

[26] Yin Huilong, Zhang Xiang, Yang Pengyuan, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming [J]. Nature Communications, 2021, 12 (1): 1394.

[27] Lheureux S, Matei D, Konstantinopoulos PA, et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer [J]. Journal of Clinical Oncology, 2020, 38 (15): 6010.